The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years.

The global RNA therapeutics and vaccines market size is estimated to grow from USD 1.2 million in 2023 to USD 948 million by 2035, representing a CAGR of 68% during the forecast period 2023-2035.

During our research, we came across initiatives undertaken by big pharma players in the next generation RNA therapeutics and vaccines domain. Over the past few years there has been a significant increase in the number of initiatives undertaken by big pharma players engaged in this domain, during the given period.

Further, it is worth highlighting that the initiatives undertaken by big pharma players were focused on research and development and product development and commercialization agreements for next generation RNA therapeutics and vaccines. Moreover, most of the big pharma players engaged in this domain carried out initiatives for research and discovery, followed by those undertaken for both clinical scales of operation.

The market opportunity associated with next generation RNA Therapeutics and Vaccines is expected to witness an annualized growth. Our estimates suggest that, in 2028, the maximum revenue generation potential is likely to be associated with RNA therapeutics / vaccines delivered via route 1, and this trend is unlikely to change in the foreseen future, as well. It is worth mentioning that the market for RNA therapeutics / vaccines administered through route 2 is anticipated to grow at a significant rate, during the period 2026-2035.

RNA Therapeutics and RNA Vaccines: Market Landscape

During our research, we were able to identify more than 100 next generation RNA therapeutics and vaccines that have either been approved or are being developed in clinical / preclinical stages for the treatment of various diseases. It is worth mentioning that majority of the next generation RNA therapeutics / vaccines are saRNA. This can be attributed to the fact that saRNAs have self amplification capability that increases the efficiency of the treatment. Other key molecules being developed include circular RNA, transfer RNA, self-activating RNA and endless RNA.

Majority of the next generation therapies are still in discovery and preclinical stages of development. It is also worth mentioning that most of the therapeutics / vaccines target infectious diseases.

Further, considering the active engagement of industry players in this domain, the market for next generation RNA therapeutics and vaccines is likely to grow in the foreseen future. It is also worth highlighting one drug candidate, namely Gemcovac (being co-developed by HDT Bio and Gennova Biopharmaceuticals) has received emergency marketing approval in India for the treatment of omicron COVID-19.

Using our proprietary methodology, we have provided informed projections, describing the likely growth of the opportunity associated with the next generation RNA therapeutics and vaccines market. We have provided our estimates on the evolution of the market till 2035. Kindly note that we have forecasted the likely revenue generation potential based on anticipated sales of drugs that are either approved or in late stages of clinical development. It is worth mentioning that, till date, only one next generation RNA vaccine, Gemcovac, has been approved for emergency use in India. As more late-stage drug candidates receive approvals in mid-long term, we expect this field to witness significant growth.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/rna-therapeutics-market.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.                   

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.chaudhary@rootsanalysis.com

Website: https://www.rootsanalysis.com/